✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Aarti Pharmalabs Ltd.

AARTIPHARM

Market Cap
₹6,836 Cr.
P/E
27.42

Aarti Pharmalabs Ltd.

  • Aarti Pharmalabs
  • Shilpa Medicare
  • Supriya Lifescience
FAQs on Aarti Pharmalabs Ltd. Shareprice

Aarti Pharmalabs has given better returns compared to its competitors.
Aarti Pharmalabs has grown at ~44.3% over the last 2yrs while peers have grown at a median rate of 43.94%

Yes, Aarti Pharmalabs is expensive.
Latest PE of Aarti Pharmalabs is 26.79, while 3 year average PE is 22.94.
Also latest EV/EBITDA of Aarti Pharmalabs is 16.06 while 3yr average is 15.3.

View FAQ's On Business
Growth Table
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Balance Sheet
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Cash Flow
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Quarterly Results
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Aarti Pharmalabs Ltd. Financials

Balance sheet of Aarti Pharmalabs is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Aarti Pharmalabs is increasing.
Latest debt of Aarti Pharmalabs is ₹326 Crs as of Sep-24.
This is greater than Mar-24 when it was ₹216 Crs.

Yes, profit is increasing.
The profit of Aarti Pharmalabs is ₹249 Crs for TTM, ₹217 Crs for Mar 2024 and ₹193 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aarti Pharmalabs latest dividend payout ratio is 12.53% and 3yr average dividend payout ratio is 10.95%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech